Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC cut its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 221,321 shares of the biopharmaceutical company’s stock after selling 4,875 shares during the period. Kennedy Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $1,060,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in VNDA. Charles Schwab Investment Management Inc. increased its holdings in Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares during the last quarter. FMR LLC grew its stake in shares of Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after buying an additional 30,802 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Vanda Pharmaceuticals by 1,184.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the period. Verition Fund Management LLC lifted its stake in Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Vanda Pharmaceuticals by 128.2% during the 3rd quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 86,677 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on VNDA shares. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, April 1st. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.36 on Tuesday. The business’s 50-day moving average is $4.62 and its two-hundred day moving average is $4.69. The firm has a market capitalization of $254.26 million, a P/E ratio of -13.63 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 1 year low of $3.85 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. On average, analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was purchased at an average cost of $4.46 per share, with a total value of $44,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,331,730 shares of the company’s stock, valued at $10,399,515.80. This trade represents a 0.43 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders bought 32,000 shares of company stock worth $151,180. Corporate insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.